Operating Income for Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's current operating income (TTM) is $1.74B USD. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingOperating IncomeSwitch metric
TTM (last 4 quarters)
$1.74B
YoY change
+18.7%
5Y CAGR
+4.8%
Peak year (2022)
$1.70B
Cumulative operating income
$17.20B
Operating Income history chart for Edwards Lifesciences (EW) from 1999 to 2025
Operating Income history table for Edwards Lifesciences (EW) from 1999 to 2025
| Fiscal year | Period ended | Reported | Operating Income | YoY |
|---|---|---|---|---|
| 2025 | $1.64B | +18.7% | ||
| 2024 | $1.38B | -3.4% | ||
| 2023 | $1.43B | -16.2% | ||
| 2022 | $1.70B | +5.7% | ||
| 2021 | $1.61B | +24.3% | ||
| 2020 | $1.30B | +8.2% | ||
| 2019 | $1.20B | +9.7% | ||
| 2018 | $1.09B | +8.1% | ||
| 2017 | $1.01B | +23.9% | ||
| 2016 | $815.50M | +41.6% | ||
| 2015 | $575.90M | +18.2% | ||
| 2014 | $487.20M | +12.5% | ||
| 2013 | $433.00M | +9.2% | ||
| 2012 | $396.70M | +20.5% | ||
| 2011 | $329.10M | +16.5% | ||
| 2010 | $282.50M | +21.2% | ||
| 2009 | $233.00M | +11.5% | ||
| 2008 | $209.00M | +23.3% | ||
| 2007 | $169.50M | +3.7% | ||
| 2006 | $163.50M | -6.9% | ||
| 2005 | $175.60M | +13.7% | ||
| 2004 | $154.40M | +11.6% | ||
| 2003 | $138.40M | +165.6% | ||
| 2002 | $52.10M | +117.1% | ||
| 2001 | $24.00M | -74.7% | ||
| 2000 | $95.00M | -18.8% | ||
| 1999 | $117.00M | — |
Operating Income values are taken from Edwards Lifesciences's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Edwards Lifesciences (EW) operating income is $1.64B – grew 18.7% year-over-year.
Edwards Lifesciences operating income has recorded the values shown across consecutive periods, with a +4.8% compound annual growth rate over 2020–2025 (5 years).
Edwards Lifesciences operating income peaked at $1.70B in 2022; the latest annual figure is $1.64B in 2025 (3.9% below peak).
2022 marks the peak operating income at $1.70B, with the historical low of $24.00M recorded in 2001.
Within Healthcare, Edwards Lifesciences (EW) ranks 9th among 8 peers we track. The peer median for operating income is $22.84B.
Edwards Lifesciences Operating Income by Year
Edwards Lifesciences Operating Income 2025: $1.64B
Edwards Lifesciences operating income in 2025 was $1.64B, grew 18.7% from 2024.
Edwards Lifesciences Operating Income 2024: $1.38B
Edwards Lifesciences operating income in 2024 was $1.38B, edged down 3.4% below 2023.
Edwards Lifesciences Operating Income 2023: $1.43B
Edwards Lifesciences operating income in 2023 was $1.43B, declined 16.2% below 2022.
Edwards Lifesciences Operating Income 2022: $1.70B
Edwards Lifesciences operating income in 2022 was $1.70B, grew 5.7% from 2021. This figure represents the highest annual value in the available history.
Edwards Lifesciences Operating Income 2021: $1.61B
Edwards Lifesciences operating income in 2021 was $1.61B.
See more financial history for Edwards Lifesciences (EW).
Sector peers — Operating Income
Companies in the same sector as Edwards Lifesciences, ranked by their latest operating income.
| Company | Operating Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $127.66B | Healthcare |
| Eli Lilly and Company (LLY) | $29.70B | Healthcare |
| Merck & Co., Inc. (MRK) | $26.78B | Healthcare |
| Johnson & Johnson (JNJ) | $25.60B | Healthcare |
| AbbVie Inc. (ABBV) | $20.09B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $18.96B | Healthcare |
| AstraZeneca PLC (AZN) | $13.74B | Healthcare |
| Amgen Inc. (AMGN) | $10.68B | Healthcare |
Frequently asked questions
What is Edwards Lifesciences's operating income?
- Latest reported operating income for Edwards Lifesciences (EW) is $1.74B (period ending March 31, 2026).
How has Edwards Lifesciences operating income changed year-over-year?
- Edwards Lifesciences (EW) operating income changed +18.7% year-over-year on the latest annual filing.
What is the long-term growth rate of Edwards Lifesciences operating income?
- Edwards Lifesciences (EW) operating income compound annual growth rate is +4.8% over the most recent 5 years available.
When did Edwards Lifesciences operating income hit its highest annual value?
- Edwards Lifesciences operating income reached its highest annual value of $1.70B in 2022.
What was Edwards Lifesciences operating income in 2024?
- Edwards Lifesciences (EW) operating income in 2024 was $1.38B.
What was Edwards Lifesciences operating income in 2025?
- Edwards Lifesciences (EW) operating income in 2025 was $1.64B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
EW Overview
Company profile, financial tools, and key metrics
EW Revenue Counter
Earns $199.88 every second. See per minute, hour, and day.
EW Earnings Counter
Earns $34.65 per second net profit. See per minute, hour, and day.
EW Economic Scale
Exceeds Fiji's GDP. Compare with world economies.
EW What If Invested
What if you had invested $1,000? See historical returns from any date.
EW How It Makes Money
Discover visual breakdown of $6.30B in revenue — where it comes from and where it goes.
EW Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
EW Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
EW Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
EW Buybacks
0.93% TTM buyback yield. Shareholder yield & SBC comparison.
EW Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.